{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:17:57Z","timestamp":1793117877346,"version":"4.5.0"},"update-to":[{"DOI":"10.1016\/j.intimp.2021.107831","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000}}],"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.intimp.2021.107831","type":"journal-article","created":{"date-parts":[[2021,5,29]],"date-time":"2021-05-29T15:22:39Z","timestamp":1622301759000},"page":"107831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["RETRACTED: Cyanorona-20: The first potent anti-SARS-CoV-2 agent"],"prefix":"10.1016","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3681-114X","authenticated-orcid":false,"given":"Amgad M.","family":"Rabie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.107831_b0005","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijid.2020.01.009","article-title":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health \u2013 The latest 2019 novel coronavirus outbreak in Wuhan, China","volume":"91","author":"Hui","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2021.107831_b0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.micinf.2020.02.002","article-title":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future","volume":"22","author":"Li","year":"2020","journal-title":"Microbes Infect."},{"key":"10.1016\/j.intimp.2021.107831_b0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/22221751.2020.1723441","article-title":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies","volume":"9","author":"Jiang","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.intimp.2021.107831_b0020","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2021.107831_b0025","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discoveries Ther."},{"key":"10.1016\/j.intimp.2021.107831_b0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3390\/v10020076","article-title":"RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution","volume":"10","author":"Venkataraman","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2021.107831_b0035","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.intimp.2021.107831_b0040","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2021.107831_b0045","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkp274","article-title":"Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells","volume":"64","author":"Smee","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.intimp.2021.107831_b0050","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"key":"10.1016\/j.intimp.2021.107831_b0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00766-18","article-title":"Orally efficacious broad-spectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses","volume":"62","author":"Yoon","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.intimp.2021.107831_b0060","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00487-17","article-title":"Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): Key role of the F1 motif of the viral polymerase","volume":"91","author":"Abdelnabi","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2021.107831_b0065","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/cpt.1844","article-title":"Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection","volume":"108","author":"Du","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2021.107831_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"23","author":"Lipinski","year":"1997","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.intimp.2021.107831_b0075","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2021.107831_b0080","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.intimp.2021.107831_b0085","doi-asserted-by":"crossref","first-page":"e68347","DOI":"10.1371\/journal.pone.0068347","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2021.107831_b0090","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1128\/JVI.02346-12","article-title":"T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro","volume":"87","author":"Baranovich","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.intimp.2021.107831_b0095","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","article-title":"T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections","volume":"82","author":"Furuta","year":"2009","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2021.107831_b0100","doi-asserted-by":"crossref","first-page":"104793","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.intimp.2021.107831_b0105","doi-asserted-by":"crossref","first-page":"e109180","DOI":"10.1371\/journal.pone.0109180","article-title":"Chloroquine is a zinc ionophore","volume":"9","author":"Xue","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.intimp.2021.107831_b0110","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1021\/jf5014633","article-title":"Zinc ionophore activity of quercetin and epigallocatechin-gallate: From Hepa 1\u20136 cells to a liposome model","volume":"62","author":"Dabbagh-Bazarbachi","year":"2014","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.intimp.2021.107831_b0115","doi-asserted-by":"crossref","unstructured":"A.M. Rabie, CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy, Mol. Divers. (2021) https:\/\/doi.org\/10.1007\/s11030-020-10169-0 (in press).","DOI":"10.1007\/s11030-020-10169-0"},{"key":"10.1016\/j.intimp.2021.107831_b0120","doi-asserted-by":"crossref","first-page":"109480","DOI":"10.1016\/j.cbi.2021.109480","article-title":"Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles","volume":"343","author":"Rabie","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.intimp.2021.107831_b0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.34297\/AJBSR.2019.02.000566","article-title":"Review on the role of Zn2+ ions in viral pathogenesis and the effect of Zn2+ ions for host cell-virus growth inhibition","volume":"2","author":"Ishida","year":"2019","journal-title":"Am. J. Biomed. Sci. Res."},{"key":"10.1016\/j.intimp.2021.107831_b0130","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.intimp.2021.107831_b0135","doi-asserted-by":"crossref","first-page":"e1001176","DOI":"10.1371\/journal.ppat.1001176","article-title":"Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture","volume":"6","author":"te Velthuis","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.intimp.2021.107831_b0140","doi-asserted-by":"crossref","first-page":"109815","DOI":"10.1016\/j.mehy.2020.109815","article-title":"Does zinc supplementation enhance the clinical efficacy of chloroquine\/hydroxychloroquine to win today's battle against COVID-19?","volume":"142","author":"Derwand","year":"2020","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.intimp.2021.107831_b0145","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s11696-018-0654-9","article-title":"The complete synthesis of favipiravir from 2-aminopyrazine","volume":"73","author":"Guo","year":"2019","journal-title":"Chem. Pap."},{"key":"10.1016\/j.intimp.2021.107831_b0150","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2174\/1389557511313110007","article-title":"Unequivocal role of pyrazine ring in medicinally important compounds: A review","volume":"13","author":"Miniyar","year":"2013","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.intimp.2021.107831_b0155","unstructured":"Molinspiration Cheminformatics (2020) (accessed and cited in 11\u201322 May, 2020). http:\/\/www.molinspiration.com."},{"key":"10.1016\/j.intimp.2021.107831_b0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/cc9800071","article-title":"A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases","volume":"1","author":"Ghose","year":"1999","journal-title":"J. Comb. Chem."}],"updated-by":[{"DOI":"10.1016\/j.intimp.2025.114980","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"record-id":"66069"},{"DOI":"10.1016\/j.intimp.2021.107831","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000}},{"DOI":"10.1016\/j.intimp.2025.114980","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000}}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921004677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921004677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T11:41:20Z","timestamp":1747309280000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921004677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":32,"alternative-id":["S1567576921004677"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107831","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RETRACTED: Cyanorona-20: The first potent anti-SARS-CoV-2 agent","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107831"}}